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xABSTRACT
Peng, Bo. M.S., Purdue University, May 2019. Applications of Data Mining in 
Healthcare. Major Professor: George Mohler.
With increases in the quantity and quality of healthcare related data, data mining tools 
have the potential to improve people’s standard of living through personalized and pre-
dictive medicine. In this thesis we improve the state-of-the-art in data mining for several 
problems in the healthcare domain. In problems such as drug-drug interaction prediction 
and Alzheimer’s Disease (AD) biomarkers discovery and prioritization, current methods ei-
ther require tedious feature engineering or have unsatisfactory performance. New effective 
computational tools are needed that can tackle these complex problems.
In this dissertation, we develop new algorithms for two healthcare problems: high-
order drug-drug interaction prediction and amyloid imaging biomarker prioritization in 
Alzheimer’s Disease. Drug-drug interactions (DDIs) and their associated adverse drug re-
actions (ADRs) represent a significant detriment to the public health. Existing research on 
DDIs primarily focuses on pairwise DDI detection and prediction. Effective computational 
methods for high-order DDI prediction are desired. In this dissertation, I present a deep 
learning based model D3I for cardinality-invariant and order-invariant high-order DDI pre-
diction. The proposed models achieve 0.740 F1 value and 0.847 AUC value on high-order 
DDI prediction, and outperform classical methods on order-2 DDI prediction. These re-
sults demonstrate the strong potential of D3I and deep learning based models in tackling 
the prediction problems of high-order DDIs and their induced ADRs.
The second problem I consider in this thesis is amyloid imaging biomarkers discovery, 
for which I propose an innovative machine learning paradigm enabling precision medicine 
in this domain. The paradigm tailors the imaging biomarker discovery process to individ-
ual characteristics of a given patient. I implement this paradigm using a newly developed
xi
learning-to-rank method PLTR. The PLTR model seamlessly integrates two objectives for
joint optimization: pushing up relevant biomarkers and ranking among relevant biomarkers.
The empirical study of PLTR conducted on the ADNI data yields promising results to iden-
tify and prioritize individual-specific amyloid imaging biomarkers based on the individual’s
structural MRI data. The resulting top ranked imaging biomarkers have the potential to aid
personalized diagnosis and disease subtyping.
11. INTRODUCTION
Adverse drug reactions and Alzheimer’s Disease (AD) are two significant public health
problems [1, 2] and a number of research efforts in the data mining community have been
dedicated to solve these problems. Zhang et al. [3] applied multiple classical methods such
as neighbor-based recommendation, random walk and matrix perturbation to predict and
rank DDI on drug pairs. Wang et al. [4] incorporated different types of drug features to
learn drug embedding of single drugs. Then they employed deep neural networks to pre-
dict the probability of single drugs in inducing side-effects. There are also several methods
proposed to extract mentioned drug pairs via text mining from medical literature and elec-
tronic medical records [5–9]. For AD detection, there is a large body of neuroimaging
studies that develop image-based predictive models for early detection of AD as well as
identification of relevant biomarkers [10–12]. However, the existing studies have several
limitations and unsolved problems remain. For DDI prediction, few studies, to the best of
our knowledge, have addressed representing, quantifying, discovering and visualizing rela-
tions among high order DDIs. However, high order DDIs comprise a significant portion of
real life adverse drug interaction cases [6, 13–15]. In most AD detection studies, proposed
models are limited to identifying imaging biomarkers that are at the population level, but
not specific to individuals.
In recent years, new computational methods such as deep neural networks (DNNs),
convolutional neural networks (CNNs), recurrent neural networks (RNNs) and attention
mechanisms have shown promise in solving complicated problems that were previously
considered infeasible. These deep models achieve impressive results in image-based di-
agnosis [16] and electronic health records (EHRs) based prediction tasks [5–9]. However,
there remain many problems in the healthcare domain that are yet to be solved by deep
learning.
2In this dissertation, I study two challenging problems:
• high-order drug-drug interaction prediction; and
• amyloid imaging biomarker prioritization in Alzheimer’s Disease.
I propose data-driven approaches (i.e. deep learning, learning to rank) to the two prob-
lems and conduct comprehensive experiments to test the proposed approaches on public
datasets. The experimental results demonstrate the strong potential of the proposed meth-
ods in solving DDI and AD prediction tasks. The performance of the proposed methods
also demonstrates the potential of applying newly developed data-driven approaches to
solve complex healthcare related problems more generally.
1.1 Thesis Outline
The remaining sections of the dissertation are organized as follows. In Chapter 2, I
will describe a deep learning method for high-order drug-drug interaction prediction. In
Chapter 3, I will describe amyloid imaging biomarker prioritization in Alzheimer’s Dis-
ease via learning to rank in detail. Finally, I will summarize the dissertation in Chapter 4.
Supplementary materials are provided in the appendix.
32. DEEP LEARNING FOR HIGH-ORDER DRUG-DRUG
INTERACTION PREDICTION
2.1 Introduction
Drug-drug interactions (DDIs) and their associated adverse drug reactions (ADRs) rep-
resent a significant detriment to the public health. Approximately 195,000 hospitalizations
and 74,000 emergency room visits are resulted out of DDIs in the United States [1]. The
increasing rates of polypharmacy, particularly among aging populations [1], will further de-
teriorate this situation [13]. Consequent upon these facts, significant research efforts have
been dedicated to detecting DDIs, including DDI extraction from medical literature [6, 7]
or social media [17–19], and biochemical and molecular information integration for DDI
scoring [20–22,22,23], etc. However, most of the existing DDI studies are limited to inter-
actions between pairs of drugs (i.e., order-2 DDIs), while DDIs among multiple drugs (i.e.,
high-order DDIs) occupy a significant portion in real-life cases. It is reported that more
than 76% of the elderly Americans take two or more drugs daily [1]. Another study [6]
estimates that about 29.4% of elderly American patients taking six or more drugs every
day. Therefore, understanding high-order DDIs and their associated ADRs becomes urgent
and critical [13–15].
Unfortunately, very limited efforts, to the best of our knowledge, have been dedicated
to representing, quantifying, discovering and visualizing relations among high-order DDIs.
Emerging methods on high-order DDI studies are only focused on the discovery of high-
order DDIs through mining frequent drug combinations efficiently. Meanwhile, as the car-
dinality of drug combinations (i.e., the number of drugs in drug combinations; also refereed
to as the order of drug combinations) increases, modeling of DDI relations, particularly of
arbitrary cardinalities/orders in a unified framework, becomes increasingly non-trivial.
4In this chapter, we present a new deep model to conduct cardinality- and order-invariant
high-order DDI prediction, refereed to as Deep DDI model and denoted as D3I. D3I is in-
variant of drug combination cardinalities and the order in which the drugs are considered in
the model, that is, D3I is able to predict ADR labels for combinations of arbitrary numbers
of drugs in arbitrary input orders. Meanwhile, D3I is able to generate embeddings for sin-
gle drugs and aggregate single drug embeddings into drug-combination embeddings. Thus,
these drug-combination embeddings are able to capture the synergistic latent signals that
are related to ADRs among the constituent single drugs. We conducted extensive exper-
iments on two public datasets of high-order DDIs, and tested multiple D3I variations on
the datasets. Our experimental results demonstrate that D3I is able to achieve 0.740 F1
value and 0.847 AUC value on balanced high-order DDI prediction, and outperform other
models on order-2 DDI prediction. The experiments also show that by integrating DDIs of
high orders, D3I models are even able to further improve prediction performance on order-2
DDIs. In addition, the single drug embeddings produced from D3I models also represent
clustering structures that conform to domain knowledge. To the best of our knowledge, D3I
is the first deep model for high-order DDI prediction.
The rest of this chapter is organized as follows. Section 2.2 presents the literature re-
view. Section 2.3 presents the definitions and notations used in this chapter. Section 2.4
presents the D3I method. Section 2.5 presents the datasets used for the experiments. Sec-
tion 2.6 presents the experimental protocol. Section 2.7 presents the experimental results.
Section 2.8 presents conclusions and future research.
2.2 Literature Review
2.2.1 DDI Detection and Prediction
Current research on detecting DDIs can be broadly classified into four categories [13,
21, 24, 25]. The first category of methods focus on text mining from medical literature and
electronic medical records, and they extract mentioned drug pairs [5–9]. A second category
of methods integrate various biochemical and molecular drug/target data to measure drug-
5drug similarities and score/predict DDIs using the similarities. These data include chemical
structures [20, 26], target information [21, 27], compound-target docking results [28], phe-
notypic and genomic information [22], and drug side effects [23], etc. The collected data
are used in various data-driven computational methods such as classification [22], regres-
sion [23], statistical testing [29] to detect DDIs. For example, Zhang et al. [3] applies
multiple methods such as neighbor-based recommendation, random walk and matrix per-
turbation for pairwise DDI ranking and prediction. The third category of methods leverage
healthcare information on social media and online communities to detect DDIs that have
been mentioned/inferred in online discussions and posts [17–19]. The last category of
methods predict the probability of ADR event counts due to high-order DDIs [30, 31] and
use either electronic medical records or pharmacokinetic modeling to validate potential
DDIs. A notable shortcoming of these methods is that they work for low-order or fixed-
order DDIs but do not scale well to arbitrary orders.
2.2.2 Deep Learning based DDI Detection and Prediction
The interactions between drugs are very complex and may go far beyond simple or
linear relations. Thus, it inspires the use of Deep Learning (DL) in this field due to the
strong capability of DL in approximating complex relations. High-order DDIs prediction
has some analogies to multi-instance learning [32] over bags of instances. Wang et al. [32]
proposed a deep framework for multi-instance learning, which first learns an embedding for
each of the instances in the bag, and then applies an aggregator to combine these embed-
dings into a bag-level representation for classification. llse et al. [33] proposed an attention-
based deep model to integrate instance embeddings into bag embeddings. One drawback
of this method is that it combines instances linearly, which might not always be optimal.
Zaheer et al. [34] introduced constraints on the weight matrix of the deep model to learn
over sets, and enforced symmetry of the learned weight matrix to enable order-invariant
property into the model. Wang et al. [4] incorporated different types of drug features to
6learn a drug embedding for single drugs, and used a deep neural network architecture to
predict potential side-effects of single drugs.
Deep learning technologies are also used in detecting and predicting DDIs. Segura-
Bedmar et al. [35] proposed to use convolutional neural networks (CNNs) to extract DDIs
from biomedical text. Text information is represented as a matrix, in which each column
or row is a word vector [36]. Then CNN layers are applied to the matrix to extract features
and do the prediction. This work achieves the second place in the 2013 ranking of the DDIs
extraction challenge. In Sahu et al. [37], instead of using CNNs, Long Short-Term Memory
(LSTM) model is used to extract features from text and then do the prediction. Graph
Convolutional neural Network (GCN) is also introduced to predict pairwise DDIs. Zitnik
et al. [38] views pairwise DDI prediction as a link prediction task over drug-drug graphs.
They applied GCN on the constructed DDI graph to learn embeddings for each drug, and
calculated link probabilities (i.e., DDI probabilities) based on learned embeddings.
2.3 Definitions and Notations
Table 2.1.
Notations
notation meaning
d a drug
D a drug combination
f a vector of drug features
e a vector of drug embedding
E a vector of drug combination embedding
The key notations used in this chapter are listed in Table 2.1. In this cgapter, all the
vectors are by default row vectors and represented using lower-case bold letters (e.g., e);
7all the matrices are represented using upper-cases letters (e.g., X). The key definitions used
in this chapter are listed as follows:
• Drug combination: a set of drugs that are prescribed/taken together, denoted as D.
• Cardinality of drug combinations: the number of drugs in a drug combination D is the
cardinality of the drug combination, denoted as ‖D‖. Drug combination cardinality
is also refereed to as drug order of the combination.
• Cardinality invariance: the model is able to predict for drug combinations of arbi-
trary cardinalities; the prediction mechanism is invariant of the cardinalities of input
drug combinations.
• Order invariance: the model is able to produce a same result for a same drug combi-
nation, regardless of the order in which the drugs in the combination are input to the
model. Note that in order invariance, the term “order” does not refer to cardinality
but to a notion of ordering.
The problem that we try to solve is defined as follows:
Problem definition: Given a set of drug combinations and their ADR labels, build a
classification model of cardinality invariance and order invariance that is able to predict the
ADR labels for new drug combinations of arbitrary cardinalities.
In this chapter, we are only concerned with one specific ADR, that is, myopathy [39].
Therefore, the classification model is a binary classifier. However, multi-class classifier
can be extended from our models, and will be investigated in our future research. In this
study, we a use feature vector to represent each drug. The feature vector is consisted by the
pairwise similarities between the profile of different drugs.
2.4 Methods
We develop a new deep model to conduct cardinality- and order-invariant high-order
DDI prediction. This model is refereed to as Deep DDI model and denoted as D3I. D3I has
the following three key components:
8• An encoder, which encodes each of the drugs in an input drug combination into a
latent representation (i.e., embedding);
• An aggregator, which learns a single, high-level representation/embedding for the
drug combination from the representations/embeddings of its component drugs; and
• A predictor, which predicts the likelihood of ADR labels using the drug-combination
representation/embedding.
Figure 2.1 presents the architecture of D3I. The novelty of D3I is that its aggregator is
able to deal with arbitrary number of drug embeddings in drug combinations regardless of
drug input orders. Meanwhile, the single drug embeddings and the drug-combination em-
beddings could enable additional insights on the drug properties and relations in inducing
ADRs.
Note that in this chapter, only myopathy is considered as the ADR of interest. That is,
we predict if a drug combination will induce myopathy or not. The reason for myopathy as
the interested ADR is that it has been better studied [40] than other side effects, particularly
in terms of the underlying mechanisms and the ground-truth myopathy-inducing single
drugs. Even though, our D3I is effortlessly applicable to other specific, single ADRs, and
can be easily extended to the prediction of multiple, specific ADRs (by learning multiple
outputs) and to the prediction of general ADRs (i.e., whether there will be ADRs or not;
not specific to a certain type of ADR).
2.4.1 D3I Encoder
The D3I encoder learns and represents signals that could be pertinent to ADR prediction
from each drug in the input drug combination. For a drug combination D= {d1,d2, · · · ,dn}
of n drugs, the encoder ge learns an embedding ei for each drug di from its feature vector
fi as follows:
ei = ge(fi), (2.1)
9drug features fn dn
drug combination D = {d1,d2, · · · ,dn}
drug embedding en
drug· · · · · ·
d· · ·
drug features f2 d2
drug embedding e2
drug features f1 d1
drug embedding e1
encoder
drug combination embedding E
logistic sigmoid
ADR score
aggregator
predictor
Fig. 2.1. D3I Architecture
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where ei ∈ R1×k, fi ∈ R1×m and typically k < m. We use an ne-layer neural network (NN)
as ge, that is,
ge(f) = gne(· · ·(g2(g1(f))), (2.2)
with each layer parameterized by a weighting matrix W ej ( j = 1, · · · ,ne) of appropriate
dimensions. The input drug features will be discussed later in Section 2.5. Note that the
encoder applies on each individual drug in the input drug combination independently, and
thus it is order invariant. For input D = {d1,d2, · · · ,dn}, the output from the encoder is
denoted as e(D) = [e1;e2; · · · ;en], that is, e(D) is a n× k matrix.
2.4.2 D3I Aggregator
The D3I aggregator learns one embedding for the input drug combination from its in-
dividual drug embeddings out of the encoder. We adopt three aggregation strategies: 1).
max pooling, 2). mean pooling and 3). aggregation with attentions, respectively, in the D3I
aggregator.
Max Pooling
In the max pooling strategy, we calculate the drug-combination embedding, denoted as
ED, for D = {d1,d2, · · · ,dn} as follows:
ED = max(e(D)) = [max∀i
{ei,1},max∀i {ei,2}, · · · ,max∀i {ei,k}], (2.3)
where max is an element-wise operator that selects the maximum value in each dimension
in all the drug embeddings e(D) = [e1;e2; · · · ;en]. The max pooling is trivially cardinality
invariant and order invariant due to the max function used. It is expected that drugs con-
tribute differently in their interactions and induced ADRs, and their respective contributions
could be represented in their maximum values in their embeddings through learning and
the max pooling. D3I with the max pooling strategy is denoted as D3Imax.
11
Mean Pooling
In the mean pooling strategy, we calculate the drug-combination embedding ED as fol-
lows:
ED = mean(e(D)) = [avg∀i{ei,1},avg∀i{ei,2}, · · · ,avg∀i{ei,k}], (2.4)
where the avg operator calculates the average value in each dimension in all the drug em-
beddings e(D) = [e1;e2; · · · ;en]. The mean pooling is also trivially cardinality invariant and
order invariant. It intends to average the information from each involved drug in represent-
ing a drug combination. D3I with the mean pool strategy is denoted as D3Imean.
Self-Attention
Inspired by the recent work in deep multi-instance learning [33], we propose to use a
weighted sum of drug embeddings to learn a single embedding of a drug combination. For
a drug combination D = {d1,d2, · · · ,dn}, the embedding of D is calculated as follows:
ED =
n
∑
i=1
aiei, (2.5)
where ai is a weight on ei. To allow the drug embeddings to determine their own importance
in the drug-combination embedding, ai is also calculated as a function of ei as follows,
ai = softmax(w tanh(V eTi )),
where V ∈ Rl×k and w ∈ R1×l are two parameters that will be learned, and softmax(x) is
the softmax function defined as follows:
softmax(xi) =
exp(xi)
∑ j exp(x j)
, (2.6)
and thus ∑i ai=∑i(softmax(wT tanh(V eTi )))=1; and the hyperbolic tangent function tanh(·)
is used to introduce element-wise non-linearity. The attention mechanism as in Equa-
tion 2.5 is order invariant simply because the sum operation in Equation 2.5 is order invari-
ant. It is also cardinality invariant because of the normalization in softmax in Equation 2.6.
D3I with the self-attention pooling strategy is denoted as D3IAtt.
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2.4.3 D3I Predictor
The D3I predictor predicts the probability of a drug combination in inducing ADRs.
For a drug combination D, its embedding ED is first converted through np fully-connected
layers with tanh as the activation function, that is,
he(ED) = hnp(· · ·(h2(h1(ED)))), (2.7)
with each layer parameterized by a weighting matrix W Ej ( j = 1, · · · ,np) of appropriate
dimensions. Then a sigmoid function is used to do the prediction as follows:
p(D) =
1
1+ exp(−he(ED)T)
(2.8)
where ED is the drug-combination embedding of D out of D3I aggregator, and p(D) is the
probability of D in inducing ADRs (p(D) ∈ [0,1]).
2.4.4 Learning Algorithm
In D3I, we formulate the DDI-induced ADR prediction as a binary classification prob-
lem, and learn the D3I models by solving the following optimization problem, in which the
cross entropy loss is used as the objective:
min
Θ
−
n
∑
i=1
yi log pi+(1− yi) log(1− pi), (2.9)
where yi is the label of the i-th drug combination (positive for ADR inducing and negative
otherwise), pi as calculated in Equation 2.8 is the probability of i-th drug combination in
inducing ADRs, and Θ is the set of parameters of the D3I model, including the weight-
ing matrices {W e} (in D3I encoder as in Section 2.4.1) and {W E} (in D3I predictor as in
Section 2.4.3) among the fully-connected layers. We use the Adam gradient descent algo-
rithm [41] to solve the problem 2.9. We use batch training, described in Section A.2.1 in
the supplementary materials, to train D3I models. All the hyper-parameters are reported in
Section A.2.2 in the supplementary materials.
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2.4.5 Data Availability
The data and the code will be made publicly available upon the acceptance of this
chapter.
2.5 Materials
We use two datasets in our experiments to test the performance of D3I. The first dataset
is derived from Chiang et al. [42], denoted as FEARS. The second dataset is derived from
Zhang et al. [3], denoted as BMC. The dataset statistics is presented in Table 2.2.
Table 2.2.
Dataset Statistics
dataset #d #D ‖D‖ ¯‖D‖ features
FEARS 826 6,338 2-52 3.6 substructures (FP), targets (TG), side effects
(SE), indications (TI)
BMC 548 48,584 2 2 substructures (FP), targets (TG), off-side ef-
fects (OSE), indications (TI), enzymes (EM),
pathways (PW), transporters (TP)
The columns corresponding to #d, #D, ‖D‖, ¯‖D‖ and “features” have the number of drugs,
the number of drug combinations, the cardinalities of drug combinations, average cardinaltiy
of drug combinations and the drug features in the dataset, respectively.
2.5.1 FEARS Dataset
The FEARS dataset has 6,338 drug combinations from 826 drugs, including 2,981
2-drug combinations, 1,555 3-drug combinations, 652 4-drug combinations, 323 5-drug
combinations, 220 6-drug combinations, 157 7-drug combinations and 450 combinations
with more than 7 drugs. The maximum number of drugs in a combination is 52, and the
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average is 3.6. The drug combinations are selected based on their odds ratios [43] of in-
ducing myopathy among a large collection of spontaneous reports to FDA1 The detailed
description of drug combination selection and dataset construction is available in Section 8
”Data Preparation” in Chiang et al. [42]. We collected 4 types of information for the drugs,
including chemical substructure fingerprints (FP), side-effect profiles (SE), therapeutic-
indication profiles (TI) and target profiles (TG). Unfortunately, we cannot find all the 4
types of features for each drug. As a result, the size of used data when using different fea-
tures as input is different, that is, 6,638 combinations with FP, 3,330 combinations with SE,
3,088 combinations with TI, and 5,621 combinations with TG. The detailed description on
such features is available in Section A.1 in the supplementary materials. Please note that in
FEARS, half of the drug combinations induce myopathy (i.e., positive drug combinations)
and the rest do not (i.e., negative drug combinations).
2.5.2 BMC Dataset
The BMC has 48,584 drug pairs from 548 drugs with 9 different types of drug features,
including chemical substructures denoted as FP, drug target profiles denoted as TG, trans-
porter profiles denoted as TP, enzymes denoted as EM, pathways denoted as PW, drug
indications denoted as TI, side effects denoted as SE, off-side effects denoted as OSE and
the drug-drug interaction profiles. We download the drug similarity profiles calculated from
the 7 types of features2. For more details about the drug features, drug similarity profiles
and BMC, please refer to Zhang et al. [3]. Note that in BMC, the drug combinations all
induce side effects (i.e., positive drug combinations).
2.5.3 Generation of Drug Feature Vectors
For each dataset, we calculate the pairwise Jaccard similarity coefficients for all the
drugs in the dataset using each of the drug features (e.g., TG, TI), and use each row of the
1https://www.fda.gov/drugs/informationondrugs/ucm135151.htm
2https://github.com/zw9977129/drug-drug-interaction/
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similarity matrix as the corresponding feature vector representation of the corresponding
drug. Intuitively, the feature vector f of a drug d presents the similarities between d and all
drugs in the same dataset using the corresponding drug features. This feature representation
scheme is inspired by the idea in Que and Belkin [44]. It provides an easy framework
to mitigate high-dimension features with missing values and integrate multiple types of
features.
2.6 Experimental Protocols
2.6.1 Positive and Negative Data Generation
We conduct the experiments under two settings, denoted as TPTN and TPRN, respec-
tively. In TPTN, we use the true positive and true negative drug combinations from the
datasets to train and test our models. That is, the positive and negative samples are fixed
from the datasets. In TPRN, we only use the positive drug combinations in the datasets and
sample corresponding equal-size negative drug combinations for training and testing.
Negative Data Sampling in TPRN
The negative sample generation process is only conducted in the TPRN setting, that
is, for a cardinality-k positive drug combination D = {d1, ...dk}, we sample k drugs and
construct a corresponding negative drug combination D′ = {d′1, ...d′k} such that D′ is not in
the positive drug combinations. Drug d′ is selected according to the following distribution
P,
P(d′) =
f (d′)
∑ni=1( f (d′i))
, (2.10)
where f (d′) denotes the frequency of drug d′ in training and validation set (see Sec-
tion 2.6.2 for details on cross validation). Please note that sampled drug combinations
could be false negative, and thus we need to check the sampled combinations against the
training and validation set to remove false negative samples.
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The reason why we do negative sampling, even though there could be labeled nega-
tive drug combinations, is to avoid the situation in which the classification is biased by a
confounder from the cardinalities of drug combinations. We noticed that combinations of
high cardinalities are more likely to induce side effects, but true negative drug combina-
tions tend to have low cardinalities (will be discussed later in Section 2.7.3). Therefore,
a model trained from such negative drug combinations could be biased by the signals in
high-cardinality, true positive drug combinations, and the signals in low-cardinality, true
negative drug combinations. By doing the negative sampling as above, we introduce neg-
ative training instances of high cardinality, and thus force the model to learn non-trivial
signals from drug combinations.
2.6.2 Cross Validation
We conduct 5-fold cross validation in both TPTN and TPRN settings. In the TPTN
setting, we randomly split the original datasets into 5 folds of equal size, with all the folds
having relatively same number of true positive/true negative drug combinations. We use 3
folds for model training, 1 fold for validation and 1 fold for testing each time. In the TPRN
setting, we randomly split the positive drug combinations in the datasets into 5 folds of
equal size. Similar to the first setting, 3 folds are used for training, and the rest 2 folds are
used for testing and validation each time. Before training, we sample negative drug com-
binations for testing and validation sets and fix them (i.e., the negative drug combinations
will not change during and after training for the testing and validation sets). The negative
drug combinations of training set are sampled during training on the fly. That is, in each
training batch (Section A.2.1 in the supplementary materials), we sample negative drug
combinations of the same size and order distribution for the positive drug combinations in
that batch. The positive drug combinations and sampled negative drug combinations are
together used as training data in the batch to train the model. In both settings, we run ex-
periments for 5 times, with 1 fold as the testing set each time, and report results that are
averaged out of the five experiments.
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2.6.3 Evaluation Metrics
We use accuracy, precision, recall, F1 and Area Under the ROC Curve (AUC) to eval-
uate the performance of the various methods. We use TP, FN, TN and FP to denote the
number of true positive drug combinations, false negative drug combinations, true negative
drug combinations and false positive drug combinations in the testing set, respectively. We
also use P to denote the number of positive drug combinations (i.e.,P = TP + FN) and N
to denote the number of negative drug combinations (i.e., N = FP + TN). Thus, accuracy
(acc) is defined as follows,
acc =
TP+TN
P+N
, (2.11)
that is, acc is the fraction of all correctly classified drug combinations over all the drug
combinations. Precision (pre) is defined as follows,
pre =
TP
TP+FP
, (2.12)
that is, pre is the fraction of correctly classified positive drug combinations over all the drug
combinations that are classified as positive. Recall (rec) is defined as follows,
rec =
TP
TP+FN
, (2.13)
that is, it’s the fraction of correctly classified positive drug combinations over all the posi-
tive drug combinations. F1 is defined as follows,
F1 = 2× rec×pre
rec+pre
, (2.14)
that is, it’s the harmonic mean of the precision and recall. Area Under the ROC Curve
(AUC) [45] is the normalized area under the curve of the true-positive rate against the false
positive rate over different classification thresholds. For all the 5 metrics, the larger value
indicates better classification performance.
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2.7 Experimental Results
We present the experimental results in this section. Additional experimental results
including comparison on drug features and model architectures are available in Section A.3
in the supplementary materials..
2.7.1 Overall Performance
Overall performance on FEARS
Table 2.3 presents the best performance of the three methods D3Imax, D3Imean and
D3IAtt on FEARS under the two experimental settings TPTN and TPRN. Note that all
the results in the table are selected according to the best F1 values, and the other evaluation
measurements according to the best F1 values are also presented. Overall, D3Imax achieves
the best performance compared to the other two methods with the best F1 0.815 and AUC
0.892 in TPTN, and the best F1 0.740 and AUC 0.847 in TPRN. D3Imean ranks as the
second with the best F1 0.766 and AUC 0.842 in TPTN, and the best F1 0.704 and corre-
sponding AUC 0.767 (best AUC 0.770) in TPRN. D3IAtt performs the worst with best F1
0.756 and AUC 0.834 in TPTN, and best F1 0.672 and AUC 0.760 in TPRN. These results
demonstrate the strong capability of D3Imax in predicting ADRs of drug combinations of
various orders.
The primary difference among D3Imax, D3Imean and D3IAtt relies on their aggregators.
D3Imax utilizes max pooling as in Equation 2.3 to construct a combination embedding that
consists of the strong signals from each dimension of individual drug embeddings. It is
very likely that in the combination embedding, different dimensions selected via max() op-
erator are from different drugs, and therefore, non-linearity in aggregation is realized. More
importantly, such combination of embedding dimensions from different drugs corresponds
to the notation of drug-drug interaction – intuitively, drugs contribute different aspects all
together to introduce ADRs.
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The TPTN and TPRN settings are different in the negative drug combinations in both
training and testing sets. In TPTN, the negative drug combinations typically have different
cardinalities compared to those of the positive drug combinations. However, in TPRN,
our sampling method as described in Section 2.6.1 guarantees same cardinalities for each
positive drug combination and its paired, sampled negative drug combination. The overall
worse performance in TPRN compared to that in TPTN indicates the difficulty in learning
from same-dimensionality positive and negative drug combinations, and the difficulty in
learning synergistic interaction signals from high-cardinality drug combinations. However,
our methods are still able to achieve F1 0.740 and AUC 0.847 in TPRN, indicating its strong
potential in predicting high-order DDIs and induced ADRs. Compared to TPRN, the TPTN
setting is closer to the real application scenario (e.g., different cardinality distributions in
positive drug combinations and negative drug combinations), and the good performance
of our methods demonstrates their strong potential in high-order DDI prediction in real
applications.
Overall performance on BMC
Table 2.4 presents the overall performance of D3I methods and the comparison with
other methods on the BMC dataset. Please note that BMC dataset has only true positive
drug combinations of cardinality 2. The results reported in the original paper [3] corre-
spond to very unbalanced testing data (i.e., 9,716 positives, 101,294 negatives). Therefore,
the performance of neighbor-based recommender, random walk and matrix perturbation
as used in the paper [3] is good in accuracy and AUC, but not in other metrics. In D3I
methods, we conducted negative sampling and thus the testing data are balanced. In terms
of precision, recall and F1, D3I methods significantly outperform others. In particular, in
terms recall, D3IAtt is 4.6% better than random walk (recall 0.803 vs 0.768), which is the
best non-D3I method. Also, in terms of F1, D3Imax is also better than matrix perturbation
that achieves the best F1 among all the non-D3I methods (F1 0.720 vs 0.707).
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Clustering Analysis
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Fig. 2.2. Single Drug Embeddings from D3Imax (FEARS, TPRN)
Figure 2.2, generated using t-SNE [49] method, presents the single drug embeddings
generated from D3Imax (TPRN) on the FEARS dataset. In this figure, there are some well-
formed clusters (e.g., C1, C3 and C4). Cluster C1 primarily includes antipsychotic drugs
(e.g., amisulpride, aripiprazole, droperidol, perphenazine, pimozide, pipotiazine, risperi-
done), antidepressants (e.g., amitriptyline, desipramine, trazodone) and drugs for Parkinson
treatment (e.g., isuride, ropinirole) and Huntington treatment (e.g., tetrabenazine). Cluster
C3 includes many anti-inflammatory drugs (e.g., acetylsalicylic acid, flurbiprofen, ibupro-
fen, loxoprofen, naproxen, rofecoxib, salicyclic acid, tenoxicam). In cluster C4, most
of the drugs (e.g., butabarbital, clonazepam, clotiazepam, etizolam, oxazepam, pentobar-
bital, thiopental) are used to treat tension, anxiety, nervousness, insomnia, seizures and
panic disorders. Cluster C5 represents a group of drugs (e.g., codeine, heroin, oxycodone,
propoxyphene, sufentanil, tramadol) that are used to treat pains. The above clustering
structures among single drug embeddings demonstrate that D3I methods learn latent repre-
sentations from single drugs that may conform to domain knowledge.
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2.7.2 Case Study
Table 2.5 presents some examples that D3Imax is able to correctly predict on FEARS
dataset. The first 5 drug combinations have single drugs that induce myopathy on their
own (bold), and have various cardinalities. The last 5 drug combinations do not involve
any myopathy-inducing single drugs, but all the drugs together in a combination still induce
myopathy based on their odds ratios. These results show that D3I models do not trivially
learn from single drugs that induce myopathy, but learn from the synergistic signals from
multiple drugs in drug combinations for ADR prediction.
2.7.3 Comparison over Drug Combination Cardinalities
Performance Comparison over Drug Combinations of Various Cardinalities
Table 2.6 presents the cardinality distribution of drug combinations in the FEARS
dataset. The majority of the drug combinations with ADRs is of order/cardinality 2 or
3. Please note that the total number of drug combinations for different features may be dif-
ferent due to the availability of different features on the drug combinations (Section 2.5.1).
Table 2.7 and 2.8 presents the model performance over drug combinations of each cardi-
nality using TG as drug features. In the experiments, all the drug combinations of various
cardinalities are used for model training and only drug combinations of each respective
cardinality are tested. Table 2.7 shows that in TPTN setting, interestingly, all the methods
share a similar trend in their performance over cardinalities, that is, the F1 values in gen-
eral increase as the cardinalities increase. However, Table 2.8 presents that in TPRN, all the
methods tend to achieve their best performance in F1 at drug combination cardinality 3 or 4,
and the performance tends to remain similar even when the cardinality increases. In TPTN,
as cardinality increases, the true positive drug combinations become more than the true
negative drug combinations (Table 2.6). Therefore, D3I model training in TPTN is biased
by the true positive drug combinations of higher cardinalities, and the true negative drug
combinations of lower cardinalities. Consequentially, all D3I methods in TPTN tend to
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have better precision and recall performance on drug combinations of higher cardinalities.
Please note that D3I methods are cardinality-invariant and they do not use the cardinal-
ity information in prediction. The biased performance in TPTN, although not preferable,
actually demonstrates that D3I methods do learn signals from the multiple drugs in drug
combinations.
The strong ability of D3I methods in learning from multiple drugs in drug combina-
tions is also demonstrated by their performance in TPRN in Table 2.8. In TPRN, each
true positive drug combination will have a corresponding negative drug combinations of
same cardinality, and thus the learning of D3I models will not be biased by the unbalanced
distribution between positive and negative drug combinations. In TPRN, D3Imax is able
to achieve F1 values above 0.760 for cardinalities higher than 3. In particular, for higher
cardinalities, D3Imax achieves even better performance, for example, for cardinality higher
than or equal to 8, D3Imax achieves F1 value 0.811.
Performance Comparison over Order-2 Drug Combinations
Table 2.9 presents the testing results on drug pairs (i.e., drug combinations of cardi-
nality 2) using drug combinations of only cardinality 2 for model training, and using all
cardinalities for model training, in D3I methods. All the experiments are conducted in
TPRN setting to avoid biases from imbalanced training data distributions. Table 2.9 shows
that when only drug pairs are used for training (i.e., the first column block in Table 2.9),
the best F1 performance is 0.680, achieved by D3Imean (with FP as the drug features), and
the best AUC performance is 0.765, achieved by D3Imax (with TG as the drug features).
However, when drug combinations of all cardinalities are used for training (i.e., the second
column block in Table 2.9), the best F1 performance is 0.685, achieved by D3Imax (with FP
as the drug features), and the best AUC performance is 0.786, achieved by D3Imax (with
TG as the drug features). The better performance using all-cardinality drug combinations
for training demonstrates that D3I methods do not trivially consider drug combination car-
dinalities in learning and prediction, but do learn the signals from all drug combinations.
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In addition, when all-cardinality drug combinations are used for training, D3I methods are
able to capture the more and richer information carried by those drug combinations, and
thus better predict drug pairs.
2.8 Conclusions and Future Research
In this chapter, we presented our deep learning model D3I for predicting adverse drug
reactions induced by high-order drug-drug interactions. D3I is able to predict for drug
combinations of arbitrary numbers of drugs, and generate meaningful embeddings for sin-
gle drugs and drug combinations. We tested D3I on two real datasets, one involving pair-
wise drug-drug interactions and the other involving high-order drug-drug interactions. Our
experimental results demonstrate that D3I is able to achieve superior performance on high-
order drug-drug interaction prediction.
In D3I, different drug features (e.g., target profiles, side effect profiles) are used inde-
pendently. Effective integration of such features together may better represent drugs and
their properties, and thus enable better performance of deep learning models. In our fu-
ture work, we will explore feature integration and fusion in D3I models. In addition, other
information may be also highly related to drug-drug interactions and their induced ad-
verse reactions, such as protein pathways and evidences from electronic medical records.
We also plan to explore effective methods to integrate such information in D3I models to
further improve D3I performance. Interpretability and evidence support are important for
prediction methods in biomedical applications. A known issue in deep learning is its lack
of interpretability by design, and thus it is worthwhile to address the interpretability issues
of D3I (e.g., what each layer learns, what the embeddings represent) in our future research.
Mining evidences to support high-order drug-drug interactions and their adverse reactions
from literature and electronic medical records is a challenging, related task that we would
like to explore in the future.
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Table 2.3.
Overall Performance on FEARS Dataset
method
TPTN
feature acc pre rec F1 AUC
D3Imax
TG 0.823 0.862 0.773 0.815 0.892
TG 0.815 0.834 0.790 0.811 0.889
D3Imean
FP 0.773 0.790 0.744 0.766 0.842
FP 0.742 0.734 0.762 0.747 0.823
TG 0.761 0.768 0.750 0.759 0.833
D3IAtt
TG 0.758 0.768 0.744 0.756 0.834
FP 0.753 0.772 0.720 0.745 0.819
FP 0.753 0.756 0.749 0.752 0.828
method
TPRN
feature acc pre rec F1 AUC
D3Imax
TG 0.762 0.813 0.680 0.740 0.847
SE 0.700 0.689 0.748 0.714 0.784
D3Imean
TG 0.706 0.708 0.702 0.704 0.767
TG 0.707 0.717 0.683 0.699 0.770
SE 0.665 0.650 0.721 0.683 0.738
D3IAtt
TI 0.703 0.750 0.609 0.672 0.760
FP 0.649 0.647 0.661 0.653 0.719
SE 0.668 0.675 0.647 0.661 0.737
Columns “acc”, “pre”, “rec”, “F1” and “AUC” correspond to accuracy,
precision, recall, F1 and AUC. The best performance for each method
under each evaluation metric is fold. The best performance over all the
methods is underlined.
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Table 2.4.
Overall Performance on BMC Dataset (TPRN)
method feature acc pre rec F1 AUC
D3Imax OSE 0.693 0.663 0.788 0.720 0.744
D3Imean
OSE 0.687 0.669 0.742 0.703 0.743
TI 0.681 0.659 0.752 0.702 0.734
D3IAtt
OSE 0.670 0.635 0.803 0.709 0.710
TI 0.670 0.640 0.779 0.702 0.707
neighbor recommender [46] OSE 0.951 0.629 0.765 0.691 0.940
random walk [47]
TI 0.952 0.641 0.768 0.699 0.941
matrix perturbation [48] - 0.952 0.666 0.755 0.707 0.948
Columns “acc”, “pre”, “rec”, “F1” and “AUC” correspond to accuracy, precision, re-
call, F1 and AUC. The original paper [3] did not report drug features used in matrix
perturbation method. The best performance for each method under each evaluation
metric is fold. The best performance over all the methods is underlined.
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Table 2.5.
Examples of Correctly Predicted Drug Combinations by D3Imax (FEARS, TG,
TPRN)
idx drug combination
1 acetaminophen, alprazolam, amitriptyline, amlodipine, anastrozole, azithromycin,
baclofen, buprenorphine, calcium, cevimeline, ciprofloxacin, doxycycline, duloxe-
tine, escitalopram, estradiol, fentanyl, fondaparinux sodium, fulvestrant, furosemide,
gabapentin, glucosamine, hydrochlorothiazide, hydrocodone, hydromorphone, ibupro-
fen, levofloxacin, lidocaine, methadone, methocarbamol, metoprolol, montelukast,
morphine, moxifloxacin, omeprazole, oxycodone, pamidronate, pantoprazole, pen-
tosan polysulfate, potassium, pregabalin, rabeprazole, triamterene, valaciclovir,
valdecoxib, vitamin c, zoledronate, zolpidem
2 alprazolam, pioglitazone, rosuvastatin, sunitinib, tamsulosin, valsartan
3 alendronate, cetaminophen, chlorpheniramine, codeine, naproxen, prednisolone,
zopiclone
4 atenolol, pravastatin
5 diphenhydramine, hydromorphone, montelukast, omeprazole, razepam, triamci-
nolone
6 gabapentin, haloperidol, morphine, propofol
7 alprazolam, diazepam, diclofenac, dicyclomine, etizolam, losartan, sulpiride
8 atenolol levofloxacin
9 amikacin, amiodarone
10 acetaminophen, alendronate, oxycodone
The drugs that induce myopathy on their own are bold.
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Table 2.6.
Cardinality Distribution in FEARS (TPTN)
feature total 2 3 4 5 6 7 ≥8
FP
all 6,338 2,981 1,555 652 323 220 157 450
#pos 3,169 865 841 442 263 195 138 425
#neg 3,169 2,116 714 210 60 25 19 25
TG
total 5,621 2,809 1,395 544 252 169 132 320
#pos 2,821 822 795 402 222 158 121 301
#neg 2,800 1,987 600 142 30 11 11 19
The columns corresponding to “2”, “3”, ..., “≥8” represent the numbers of drug
combinations of cardinality 2, 3, ..., greater than 8. The row of “all” has the total
number of drug combinations. The row of “#pos” has the numbers of positive drug
combinations. The row of “#neg” has the numbers of negative drug combinations.
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Table 2.7.
Performance Comparison of TPTN on Different Cardinalities in FEARS
Dataset (TG)
method cardinality
TPTN
acc pre rec F1 AUC
D3Imax
2 0.810 0.749 0.532 0.621 0.821
3 0.789 0.853 0.763 0.804 0.870
4 0.819 0.879 0.875 0.877 0.848
5 0.913 0.954 0.949 0.950 0.925
6 0.918 0.944 0.971 0.956 0.563
7 0.909 0.913 0.994 0.951 0.716
≥8 0.938 0.941 0.997 0.968 0.709
D3Imean
2 0.754 0.562 0.719 0.631 0.811
3 0.763 0.836 0.726 0.776 0.836
4 0.718 0.901 0.695 0.784 0.818
5 0.777 0.972 0.768 0.857 0.880
6 0.726 0.940 0.758 0.834 0.479
7 0.791 0.928 0.838 0.877 0.716
≥8 0.877 0.951 0.914 0.931 0.735
D3IAtt
2 0.744 0.550 0.696 0.614 0.806
3 0.750 0.838 0.698 0.760 0.838
4 0.741 0.913 0.719 0.803 0.816
5 0.786 0.972 0.778 0.864 0.867
6 0.756 0.942 0.789 0.857 0.394
7 0.833 0.930 0.883 0.904 0.701
≥8 0.897 0.956 0.933 0.944 0.677
Columns “acc”, “pre”, “rec”, “F1” and “AUC” correspond to accuracy, precision,
recall, F1 and AUC. Target profiles (TG) are used as drug features. The best results
presented for each drug combination cardinality are selected based on F1.
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Table 2.8.
Performance Comparison of TPRN on Different Cardinalities in FEARS
Dataset (TG)
method cardinality
TPRN
acc pre rec F1 AUC
D3Imax
2 0.697 0.752 0.587 0.659 0.786
3 0.774 0.808 0.719 0.760 0.847
4 0.775 0.798 0.737 0.766 0.862
5 0.793 0.883 0.676 0.765 0.885
6 0.799 0.900 0.679 0.770 0.887
7 0.802 0.879 0.704 0.780 0.882
≥8 0.828 0.895 0.743 0.811 0.913
D3Imean
2 0.664 0.642 0.744 0.688 0.732
3 0.723 0.707 0.766 0.734 0.786
4 0.748 0.760 0.724 0.740 0.806
5 0.750 0.812 0.653 0.722 0.837
6 0.724 0.824 0.570 0.672 0.803
7 0.760 0.873 0.611 0.711 0.827
≥8 0.670 0.940 0.364 0.523 0.824
D3IAtt
2 0.665 0.674 0.644 0.658 0.726
3 0.651 0.652 0.645 0.648 0.735
4 0.680 0.683 0.670 0.675 0.753
5 0.662 0.693 0.583 0.631 0.761
6 0.651 0.671 0.587 0.622 0.718
7 0.689 0.731 0.595 0.653 0.773
≥8 0.632 0.687 0.508 0.576 0.733
Columns “acc”, “pre”, “rec”, “F1” and “AUC” correspond to accuracy, precision,
recall, F1 and AUC. Target profiles (TG) are used as drug features. The best results
presented for each drug combination cardinality are selected based on F1.
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Table 2.9.
Best Performance on Cardinality-2 Drug Combinations (FEARS, TPRN)
method
training with cardinality-2 drug combinations
feature acc pre rec F1 AUC
D3Imax
FP 0.655 0.637 0.724 0.677 0.710
TG 0.697 0.742 0.610 0.668 0.765
D3Imean
FP 0.666 0.652 0.714 0.680 0.725
TG 0.695 0.725 0.633 0.675 0.747
D3IAtt
TG 0.689 0.721 0.620 0.665 0.749
TG 0.687 0.736 0.589 0.653 0.736
method
training with all-cardinality drug combinations
feature acc pre rec F1 AUC
D3Imax
FP 0.672 0.659 0.715 0.685 0.729
TG 0.697 0.752 0.587 0.659 0.786
D3Imean
TG 0.651 0.630 0.742 0.680 0.732
FP 0.635 0.634 0.646 0.638 0.697
D3IAtt
TG 0.665 0.674 0.644 0.658 0.726
FP 0.617 0.610 0.656 0.629 0.687
Columns “acc”, “pre”, “rec”, “F1” and “AUC” correspond to accuracy, precision,
recall, F1 and AUC. The best performance for each method under each evaluation
metric is fold. The best performance over all the methods is underlined.
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3. PRIORITIZING AMYLOID IMAGING BIOMARKERS IN
ALZHEIMER’S DISEASE VIA LEARNING TO RANK
3.1 Introduction
Alzheimer’s disease (AD) is a national priority, with 5.5 million Americans affected
at an annual cost of $259 billion in 2017 and no available cure [2]. Brain characteristics
related to AD progression may be captured by multimodal magnetic resonance imaging
(MRI) [50] and positron emission tomography (PET) [51] scans. Thus, there is a large
body of neuroimaging studies in AD, aiming to develop image-based predictive machine
learning models for early detection of AD as well as identification of relevant imaging
biomarkers (e.g., [10–12,52]). These models are typically designed to accomplish learning
tasks such as classification [53], regression [12,54,55] or both [56]. The identified imaging
biomarkers are at the population level and not specific to an individual subject. Although
such studies can improve the mechanistic understanding of AD, they are not designed to
directly impact clinical practice.
In this work, we propose a novel learning paradigm that embraces the concept of pre-
cision medicine and tailors the imaging biomarker discovery process to the individual
characteristics of a given patient. Specifically, we perform an innovative application of
a newly developed learning-to-rank method, denoted as PLTR [57], to the structural MRI
and amyloid PET data of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) co-
hort [58]. Using structural MRI as the individual characteristics, our goal is to not only
predict individual-specific amyloid imaging biomarkers but also prioritizes them accord-
ing to AD-specific abnormality. Note that amyloid imaging is more expensive and more
invasive than structural MRI. Compared with traditional biomarker studies at the popula-
tion level, the uniqueness of our study is twofold: (1) the identified biomarkers are tailored
to each individual patient; and (2) the identified biomarkers are prioritized based on the
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individual’s characteristics, which has the potential to enable personalized diagnosis (e.g.,
determining whether or not the corresponding test is needed) and disease subtyping.
3.2 Materials and Data Processing
To demonstrate the effectiveness of the learning-to-rank method for personalized prior-
itization of the amyloid imaging biomarkers, we applied it to the ADNI cohort [58]. The
ADNI was launched in 2003 as a public-private partnership, led by Principal Investiga-
tor Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial
MRI, PET, other biological markers, and clinical and neuropsychological assessment can
be combined to measure the progression of mild cognitive impairment (MCI, a prodromal
stage of AD) and early AD. For up-to-date information, see www.adni-info.org.
Data used in the preparation of this article were obtained from the 2017 ADNI TAD-
POLE grand challenge (tadpole.grand-challenge.org/), and was downloaded from the ADNI
website (adni.loni.usc.edu). The TADPOLE data used in this study consists of structural
MRI and AV45-PET (amyloid) imaging data as well as diagnostic information. Both MRI
and amyloid imaging data have been pre-processed with standard ADNI pipelines as de-
scribed previously in [59].
In this study, we included all the regional MRI measures with field name containing
“UCSFFSX” in the TADPOLE D1 and D2 data sets. Specifically, these are FreeSurfer
regional volume and cortical thickness measures processed by the ADNI UCSF team. We
also included all the regional amyloid measures with field name containing “UCBERKE-
LEYAV45” in the TADPOLE D1 and D2 data sets. These are cortical and subcortical
amyloid deposition measures processed by the ADNI UC Berkeley team.
Originally, there are totally 12,741 participant visit records with 103 amyloid features,
125 FreeSurfer features and diagnostic information corresponding to each visit. To convert
this longitudinal data set into a cross-sectional one as well as handle the missing data issue,
we use the following procedure to generate a clean set of cross-sectional data: (1) remove
visit records that have more than 50 percent of null values across 103 amyloid features, with
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10,623 records removed; (2) extract the earliest AV45-PET visit for each participant, with
1,091 records kept; (3) remove visit records that have more than 50 percent of null values
across 125 FreeSurfer features, with 58 records removed; (4) remove features that have
more than 50 percent of null values across records, with 16 FreeSurfer features removed;
(5) remove 3 participants with no diagnostic information. Finally, 1,030 participants with
103 amyloid and 109 FreeSurfer measures are studied, including 351 health control (HC),
501 MCI and 178 AD participants. We treat both MCI and AD subjects as patients, and so
have a total of 679 cases and 351 controls.
3.3 Methods
We use the joint push and learning-to-rank method as developed in He et al. [57], de-
noted as PLTR, for personalized patient feature prioritization. Our goal is to prioritize
amyloid features for each patient that are most relevant to his/her disease diagnosis using
patients’ existing information (i.e., FreeSurfer measures extracted from MRI scans). The
underlying hypothesis is that patients with similar FreeSurfer feature profiles would have
similar ranking structures among their amyloid features. In the context of AD feature prior-
itization, PLTR learns and uses latent vectors of patients and amyloid features to score each
amyloid feature for each patient, and ranks the features based on their scores; patients with
similar FreeSurfer feature profiles will have similar latent vectors. During the learning pro-
cess, PLTR explicitly pushes the most relevant amyloid features on top of the less relevant
ones for each patient, and thus optimizes the latent patient and amyloid feature vectors so
they will reproduce the pushed ranking structures.
3.3.1 Overview of PLTR
In PLTR, the ranking of features in terms of their relatedness to MCI/AD in a patient
is determined by their latent scores on the patient. For a feature f i and a patientP p, f i’s
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latent score onP p, denoted as sp( f i), is calculated as the dot product of f i’s latent vector
vi ∈ Rl×1 andP p’s latent vector up ∈ Rl×1, where l is the latent dimension, as follows,
sp( f i) = uTp vi, (3.1)
where the latent vectors up and vi will be learned. All the features are then sorted based on
their scores on P p, with the most relevant features having the highest scores and ranked
higher than irrelevant features.
PLTR leverages ranking with push [60] to enforce the high rank of relevant features.
In PLTR, the height of an irrelevant feature f −i in P p, denoted as hs( f
−
i ,P p), is used to
measure the ranking position of f −i inP p [60], and is determined as the number of relevant
features that are ranked below f −i , that is,
hs( f −i ,P p) = ∑
f +j∈P+p
I(sp( f +j )≤ sp( f −i )), (3.2)
where P+p is the set of relevant features in patient P p, sp( f
+
j ) and sp( f
−
i ) are the scores
of f +j and f
−
i in P p, respectively, and I(x) is the indicator function (I(x) = 1 if x is true,
otherwise 0). To rank relevant features higher in a patient, PLTR minimizes the total height
of all irrelevant features in that patient (i.e., minimize the total number of relevant features
that are ranked below irrelevant features). For all the patients, PLTR minimizes the total
heights, denoted as P↑s , defined as,
P↑s =
m
∑
p=1
1
n+pn−p
∑
f −i ∈P p
hs( f −i ,P p), (3.3)
where m is the number of patients, and n+p and n
−
p are the numbers of relevant and irrelevant
features in patient P p, respectively. The normalization by n+p and n
−
p is to eliminate the
effects due to different numbers of relevant and irrelevant features across the patients.
In addition to pushing relevant features on top of irrelevant features, PLTR uses f iR f j
to represent that f i is ranked higher than f j under the relation R. The concordance index
(CI) [61] is used to measure feature ranking structures compared to the ground truth, which
is defined as follows,
CI({ f i},P,s) =
1
|{ f i P f j}| ∑f iP f j
I( f is f j), (3.4)
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where { f i} is the set of features in patient P , { f i P f j} is the set of ordered pairs of
features in patientP ( f i P f j represents that f i is more relevant, and thus ranked higher,
than f j inP), s is the scoring function (Equation (3.1)) that produces an estimated feature
ranking, f is f j represents that f i is ranked higher than f j by the scoring function s, and
I is the indicator function. Essentially, CI measures the ratio of correctly ordered feature
pairs by s among all possible pairs. Higher CI values indicate better ranking structures.
To produce correct ranking orders among relevant features in all the patients, PLTR
minimizes O+s as part of its objective, which is defined as the sum of 1− CI values (i.e.,
the ratio of mis-ordered feature pairs among all pairs) over the relevant features of all the
patients as follows,
O+s =
m
∑
p=1
[1−CI({ f +i },P p,sp)] =
m
∑
p=1
1
|{ f +i P p f +j }| ∑f +i Pp f +j
I( f +i ≺sp f +j ). (3.5)
Overall, PLTR seeks the patient latent vectors and feature latent vectors that will be
used in feature scoring function s (Equation (3.1)) such that for each patient, the relevant
features will be ranked on top and in right orders using the latent vectors. In PLTR, such
latent vectors are learned by solving the following optimization problem:
min
U,V
Ls = (1−α)P↑s +αO+s +
β
2
Ruv+
γ
2
Rcsim, (3.6)
where Ls is the overall loss function; P
↑
s and O+s are defined in Equation (3.3) and Equa-
tion (3.5), respectively; U = [u1,u2, · · · ,um] and V = [v1,v2, · · · ,vn] are the latent vector
matrices for patients and features, respectively (U ∈ Rl×m, V ∈ Rl×n, where l is the latent
dimension); α (α ∈ [0,1]) is a weighting parameter to control the contribution from push
(i.e., P↑s ) and ranking (i.e., O+s ); β and γ are regularization parameters (β ≥ 0, γ ≥ 0) on
the two regularizers Ruv and Rcsim, respectively. Note that in PLTR, only AD/MCI patients
are used for model training, as the feature prioritization is for AD/MCI patients, and makes
little sense for HCs.
In Problem (3.6), Ruv is a regularizer on U and V to prevent overfitting, defined as
Ruv =
1
m
‖U‖2F +
1
n
‖V‖2F , (3.7)
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where ‖X‖F is the Frobenius norm of matrix X . Rcsim is a regularizer on patients to con-
strain patient latent vectors, defined as
Rcsim =
1
m2
m
∑
p=1
m
∑
q=1
wpq‖up−uq‖22, (3.8)
where wpq is the similarity betweenP p andPq that is calculated using FreeSurfer features
of the patients.
3.3.2 Patient Similarities from FreeSurfer Features
We consider 109 FreeSurfer features and represent each patient as a FreeSurfer fea-
ture vector, denoted as rp = [rp1,rp2, · · · ,rpnr ], where rpi (i = 1, · · · ,nr) is a FreeSurfer
feature for patient p. Thus, for all the patients, we construct a FreeSurfer feature ma-
trix RAD = [r+1 ;r
+
2 ; · · · ;r+m+] ∈ Rm
+×nr and for all the health control subjects (HCs), a
FreeSurfer feature matrix RHC = [r−1 ;r
−
2 ; · · · ;r−m−] ∈ Rm
−×nr , where m+ and m− are the
numbers of AD/MCI patients and HCs, respectively, and nr is the number of FreeSurfer
features. We scale RAD values into the unit interval by dividing each column of RAD (i.e.,
each FreeSurfer feature) its maximum value. The normalized RAD matrix is denoted as
R¯AD, and the similarities between patients are calculated over R¯AD using the radial basis
function (RBF) kernel:
wpq = exp(−‖R¯AD(p, :)− R¯AD(q, :)‖
2
2σ2
), (3.9)
where wpq is the patient similarity used in Equation (3.8). This patient similarity measure-
ment is denoted as simU.
3.3.3 Patient Amyloid Features in Ground Truth
Similarly, each patient is also represented by an amyloid feature vector, denoted as
cp = [cp1,cp2, · · · ,cpnc ], where cpi (i = 1, · · · ,nc) is an amyloid feature for patient p. Thus,
we construct an amyloid feature matrix CAD = [c+1 ;c
+
2 ; · · · ,c+m+] for AD/MCI patients, and
an amyloid feature matrix CHC = [c−1 ;c
−
2 ; · · · ,c−m−] for HC subjects. We normalize CAD by
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dividing each column of CAD (i.e., each amyloid feature) by the mean value of the cor-
responding column in CHC. Thus, the normalization results in CAD measure the extent to
which an amyloid feature in patients deviates from that in HCs. The normalized matrix, de-
noted as C¯AD, is used as the ground truth of amyloid feature ranking. That is, the optimiza-
tion problem (3.6) tries to learn the latent vectors that reconstruct the ordering structures
in C¯AD, and through such reconstruction prioritize amyloid features that are most relevant
to patients. The reason why we use FreeSurfer features to quantitatively measure patients
and prioritize amyloid features correspondingly is that MRI imaging is non-invasive and
relatively low-cost as compared to PET imaging.
3.4 Experimental Protocol
pa
tie
nt
s
features
P1
P2
P3
P4
P5
f 1 f 2 f 3 f 4 f 5 f 6 f 7 f 8 f 9 f 10
training patients testing patients
Fig. 3.1. Data split for testing new patients
We split patients into training and testing set, such that a certain patient and all his/her
features will be either in the training set or in the testing set. We train the PLTR model using
training patients and test its performance on the testing patients. This corresponds to the
use scenario in which we want to identify the most potentially useful AD biomarkers for
new patients, based on the existing information of the patients, when such biomarkers have
not been tested on the new patients. Figure 3.1 demonstrates the data split process.
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We define average hit at k, denoted as AH@k, to evaluate the ranking performance.
AH@k is defined as follows:
AH@k(τ, τ˜) =
k
∑
i=1
I(τ˜i ∈ τ), (3.10)
where τ is the ground-truth ranking list, τ˜ is the predicted ranking list, and τ˜i is the i-
th ranked item in τ˜ . That is, AH@k calculates the number of items among top k in the
predicted lists that are also in the ground truth (i.e., hits). Higher AH@k values indicate
better prioritization performance.
We define a second evaluation metric weighted average high at k, denoted as WAH@k
as follows:
WAH@k(τ, τ˜) =
k
∑
j=1
AH@ j(τ, τ˜)/k, (3.11)
that is, WAH@k is a weighted version of AH@k that calculates the average of AH@ over
top k. Higher WAH@k indicate more hits and those hits are ranked on top in the ranking
list. By default, the ground-truth τ has k items (i.e., the top-k items among all the sorted
items) in Equation (3.10) and Equation (3.11).
3.5 Experimental Results
3.5.1 Overall Performance
We first hold out 35 and 163 patients as testing patients, respectively. These testing
patients are determined such that they have more than 10 similar patients in the train-
ing set, and the corresponding patient similarities are higher than 0.75 and 0.65, respec-
tively. Patient latent vectors and feature latent vectors are learned on the training patients.
The feature scores for the testing patients are calculated as the weighted sum of the pre-
dicted feature scores from their top-10 most similar training patients, where the weights are
the corresponding patient similarities. The patient similarities are calculated using simU
(Equation (3.9), σ = 1). The patient amyloid features are normalized as described in Sec-
tion 3.3.3. Please note that we only use patients (i.e., MCI and AD subjects) for model
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training and testing, and only use controls (i.e., HC subjects) to set the standard for pa-
tient data normalization, as feature prioritization for healthy controls has limited clinical
interests.
Table 3.1 presents the testing performance of PLTR in terms of AH@5 for each latent
dimension. When 35 patients are hold out for testing, the best AH@5 is 1.886 when latent
dimension d = 20, and the corresponding AH@10 is 3.286. This performance is signifi-
cantly better than random, which has a theoretical AH@5 value lower than 0.25 for more
than 100 features. Note that we use predicted feature scores to prioritize features for the
testing patients. A baseline is to use the weighted sum of the ground-truth feature values
from the similar training patients, which does not require any model training. This base-
line method has an AH@5 1.714 in our data, whereas the learning-based PLTR achieves
10.0% better performance (i.e., 1.886) than the baseline. When 163 patients are hold out
for testing, the best performance of PLTR (i.e., AH@5 1.429 when d = 20) is 5.9% better
than its baseline (i.e., AH@5 1.350). This indicates that PLTR is able to capture the signals
that lead to accurate feature rankings among training data, potentially correct the noise in
the data and use the signals to prioritize features for new patients.
Table 3.1 also shows that the best testing performance for the 35 testing patients is
better than that for the 163 testing patients. In addition, the performance improvement over
the baseline for the 35 testing patients is also better than that for the 163 testing patients.
This indicates that as long as there are sufficiently similar patients for modeling training,
PLTR is able to achieve stronger performance than the baseline.
Feature Prioritization on Population Level
We also investigate which features are frequently prioritized for all the testing patients.
We sort all the top-5 ranked features from all the testing patients, weighted by their aggre-
gated ranking positions among the patients, so that features that are frequently ranked high
among many patients will be sorted on top. Table 3.2 lists the top 10 of such frequently
prioritized features by PLTR among the 163 testing patients. Among these 10 features, 8 of
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Table 3.1.
Overall Performance of PLTR (simU, σ = 1)
n α β γ d AH@5 WAH@5 AH@10 WAH@10
35
0.3 0.5 1.0 10 1.857 1.545 3.371 2.249
0.3 0.5 1.0 20 1.886 1.632 3.286 1.987
0.3 0.5 1.0 50 1.857 1.560 3.314 2.007
163
0.5 1.0 1.0 10 1.343 0.930 3.080 2.497
0.5 1.0 1.0 20 1.429 1.067 3.074 2.402
0.5 1.0 1.0 50 1.429 1.012 3.110 2.437
The column “n” corresponds to the number of hold-out testing patients. Best performance under each evalu-
ation metric is in bold. Baseline AH@5 performance for n = 35 is 1.714, and for n = 163 1.350.
them are among the top 10 identified from the ground truth. Similarly, for the 35 testing
patients, 7 of the top-10 most frequently prioritized features are among the top 10 iden-
tified from the ground truth. This indicates the capability of PLTR to find common AD
biomarkers on a population level.
Most of the above top ranked amyloid features are related to AD or its biomarkers. For
example, frontal lobe, the region where frontal pole, rostral middle frontal gyrus and medial
orbitofrontal cortex are located, shows significantly higher amyloid deposition in AD/MCI
patients than in MCI [62]. Furthermore, Huang et al. [63] report that both frontal lobe and
precuneus show significantly higher amyloid deposition in both MCI and AD compared to
HC. Additionally, they report the negative correlation between MiniMental State Examina-
tion (MMSE) score with amyloid deposition in frontal lobe and precuneus, which further
validates increased amyloid deposition in these regions of MCI and AD patients.
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Table 3.2.
Top-10 frequent features by PLTR (simU, σ = 1)
rank features p-value GT
1 ctx-lh-frontal pole 8.67e-20 Y
2 ctx-rh-frontal pole 5.68e-20 Y
3 right-lateral ventricle 4.34e-04 Y
4 ctx-rh-medial orbitofrontal 4.79e-23 Y
5 left-lateral ventricle 1.09e-04 Y
6 ctx-lh-rostral middle frontal 5.12e-21 Y
7 right-choroid plexus 4.41e-05 N
8 ctx-rh-rostral middle frontal 3.68e-20 N
9 ctx-lh-precuneus 3.19e-19 Y
10 non-wm-hypointensities 8.75e-01 Y
The p-value measures whether the feature means are statistically different be-
tween controls and patients. Column “GT” indicates if the feature is in ground
truth (Y) or not (N). These features are frequently prioritized by PLTR when 163
patients are hold out for testing.
3.5.2 Study on Patient-Patient Similarities
Table 3.3 presents the testing performance when a different patient similarity is ap-
plied. In this case, the patient similarities are calculated using a RBF kernel (σ = 5) on
the FreeSurfer features of the patients, after the FreeSurfer features are divided by the cor-
responding feature mean from normal patients. This feature normalization measures how
much the FreeSurfer features in patients deviate from those in HCs. This similarity mea-
surement is denoted as simN. 62 patients are hold out for testing, who have at least 10 train-
ing patients each with patient similarities higher than 0.65. The feature ranking is done in a
same way as in Section 3.5.1. The corresponding baseline performance in terms of AH@5
is 1.081. Table 3.3 shows that the PLTR outperforms the baseline at 29.8%. Table 3.3 and
Table 3.1 together demonstrate that regardless of similar functions used to measure patient
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similarities in FreeSurfer features, PLTR is robust in outperforming baseline given that the
testing patients have sufficient similar training patients.
Table 3.3.
Overall Performance of PLTR (simN, σ = 5)
n α β γ d AH@5 WAH@5 AH@10 WAH@10
62
0.5 1.0 1.0 10 1.371 1.161 3.129 2.295
0.5 1.0 1.0 20 1.387 1.186 3.081 2.162
0.5 1.0 1.0 50 1.403 1.165 3.113 2.117
The column “n” corresponds to the number of hold-out testing patients. Best performance under each
evaluation metric is in bold. Baseline AH@5 performance for n = 62 is 1.081.
3.6 Conclusions
We have proposed an innovative machine learning paradigm enabling precision medicine
for AD imaging biomarker discovery. The paradigm tailors the imaging biomarker discov-
ery process to individual characteristics of a given patient, and has been implemented based
on a newly developed learning-to-rank method PLTR. To the best of our knowledge, this
learning-to-rank method has never been applied to the AD imaging biomarker studies. It is
a paradigm shifting strategy to facilitate precision medicine research in brain imaging study
of AD. The PLTR model seamlessly integrates two objectives for joint optimization: push-
ing up relevant biomarkers and ranking among relevant biomarkers. The empirical study
of PLTR has been performed on the ADNI data and yielded promising results to identify
and prioritize individual-specific amyloid imaging biomarkers based on the individual’s
structural MRI data.
Our overarching goal is to enable precision medicine for AD imaging biomarker dis-
covery. The proposed paradigm not only identifies individual-specific imaging biomarkers
but also prioritizes them according to AD-specific abnormality. The resulting top ranked
imaging biomarkers have the potential to aid personalized diagnosis and disease subtyping.
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With this observation, work is in progress to expand the proposed method into a new model
that can not only identify top ranked imaging biomarkers in a subject specific manner but
also use this reduced set of biomarkers for accurate prediction of outcome of interest such
as diagnostic status or conversion to AD.
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4. SUMMARY
In this dissertation, I have developed a new deep model D3I for high-order drug-drug in-
teraction prediction. To my best knowledge, it’s the first model that is able to conduct
cardinality-invariant and order-invariant high-order DDI prediction. Moreover, I have pro-
posed a novel machine learning paradigm enabling amyloid imaging biomarker discovery
and prioritization. The proposed paradigm can find the most informative amyloid features
of each patient. Therefore, the paradigm can help significantly save the diagnosis time and
reduce costs, while maintain similar diagnostic power.
Studies showed that above half of the elderly Americans take two or more drugs daily
and about one-third of elderly American patients take more than 5 drugs daily. It makes
detecting drug-drug interactions (DDI) an urgent and crucial task for keeping the patients
from adverse drug reactions. Most of the existing DDI studies facus on pairwise DDI
prediction. However, considerable amount of patients take more then 2 drugs daily. It’s
highly desired to develop efficient computational tools for arbitrary-order DDI prediction.
As a possible solution to this problem, I developed deep learning based methods, denoted
as D3I. The developed methods contain an encoder, an aggregator and a predictor. The
encoder encodes each of the drugs in an input drug combination into a latent representation.
The aggregator takes the embedding of the drugs in a drug combination as input to learn
a single high-level representation for the drug combination. The predictor then predicts
the probability of this drug combination in inducing ADRs using the drug combination
representation. In this study, I considered 3 aggregation strategies: max pooling, mean
pooling and aggregation with attentions. Their performance is evaluated and compared on
multiple public datasets. The experimental results demonstrate that the proposed methods
D3I is able to achieve promising results and D3I outperforms other classic methods on
order-2 DDI prediction.
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Another healthcare problem I have studied is prioritizing amyloid imaging biomarkers
in Alzheimer’s Disease. Alzheimer’s Disease (AD) is an irreversible brain disorder that
will cause memory loss, think skills loss and, eventually, the loss of viability. Currently,
no drugs are able to cure AD and there is no valid treatment for patients whose condition
begins to deteriorate. Therefore, detecting AD in the early stage is crucial for the further
treatment. In this dissertation, I have proposed a novel machine learning paradigm that
enabling individual-specific amyloid imaging biomarkers discovery and prioritization that
can help detect the progression of AD. I implemented the paradigm using a newly de-
veloped learning-to-rank method PLTR, which learns the latent representation of patients
and amyloid features. The learned representations are used to score the relevancy of amy-
loid features to patients. We then rank the features based on their scores. I evaluated
the paradigm on a subset of Alzheimers Disease Neuroimaging Initiative (ADNI) cohort,
which includes 103 amyloid features and 109 FreeSurfer features. The experimental re-
sults are promising and demonstrate that the top ranked imaging biomarkers (i.e. amyloid
features) have the potential to aid personalized diagnosis and disease subtyping.
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A. SUPPLEMENTARY MATERIALS
A.1 Drug Features for FEARS
A.1.1 Chemical Substructure Fingerprints (FP)
Drug chemical structure fingerprints are commonly used as drug features. Chemi-
cal structures are highly related to drug physicochemical properties, which may correlate
to the intrinsic reasons of drug-drug interactions. We extracted the substructure finger-
prints for each drug from PubChem1. The substructure fingerprints are composed of 881
substructure-keys, each corresponding to a predefined substructure. The binary values on
each substructure-key represent whether the drug has the corresponding substructure or
not. This type of drug feature is denoted as FP.
A.1.2 Side-Effect Profiles (SE)
Drug side-effect profile is a high-level representation of drug properties. Two drugs
with similar side effect profiles may have similar underlying mechanisms. We extracted
drug side-effect profile from Side Effect Resource (SIDER) [64]2 and constructed binary
drug side-effect profiles. Each dimension in the profiles corresponds to a specific drug side
effect. The binary values on the dimensions represent whether the drug has the correspond-
ing side effect or not. We found side effect information for 529 out of 826 FEARS drugs.
These 529 drugs correspond to 3,330 drug combinations, with a maximum cardinality 18,
minimum cardinality 2 and mean cardinality 2.9. In addition, these drug combinations in-
clude 1,896 2-drug combinations, 823 3-drug combinations, 296 4-drug combinations, 114
1https://pubchem.ncbi.nlm.nih.gov
2http://sideeffects.embl.de/
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5-drug combinations, 78 6-drug combinations, 47 7-drug combinations and 76 over 7-drug
combinations. This type of drug feature is denoted as SE.
A.1.3 Therapeutic-Indication Profiles (TI)
With a similar intuition as in side-effect profiles, we also consider drug theraputic-
indication profiles in our experiments. We extracted drug theraputic-indication profiles
also from SIDER, and constructed theraputic-indication profiles in a similar way as to
construct SE. Still, we could not find theraputic-indication profiles for all the drugs in Fears
dataset. We found therapeutic indication information for only 491 out of 826 FEARS drugs.
These 491 drugs correspond to 3,088 drug combinations, with a maximum cardinality 14,
minimum cardinality 2 and mean cardinality 2.8. In addition, these drug combinations
include 1,812 2-drug combinations, 751 3-drug combinations, 243 4-drug combinations,
102 5-drug combinations, 72 6-drug combinations, 39 7-drug combinations and 69 over
7-drug combinations. This type of drug feature is denoted as TI.
A.1.4 Target Profiles (TG)
Drug target profile is a high-level representation of drug biological properties, and two
drugs with similar target profiles may have similar biological properties. We extracted
drug target information from DrugBank [65] and constructed binary drug target profiles.
Each dimension in the profiles corresponds to a specific drug target. The binary values
on the dimensions represent whether the drug has the corresponding target or not. We
found target information for 704 out of 826 FEARS drugs. These 704 drugs correspond to
5621 drug combinations, with a maximum cardinality 47, minimum cardinality 2 and mean
cardinality 3.3. In addition, these drug combinations include 2809 2-drug combinations,
1395 3-drug combinations, 544 4-drug combinations, 252 5-drug combinations, 169 6-drug
combinations, 132 7-drug combinations and 320 over 7-drug combinations. This type of
drug feature is denoted as TG.
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A.2 Model Training
A.2.1 Batch Training and Roll-Back
We initialize all the parameters using the initialization method described in [66] to
ensure that the gradient flow is smooth in the training. During the training, we also employ
the mini-batch strategy [67] for regularization and efficiency purposes. After the training,
we employ a roll-back strategy in order to avoid overfitting. That is, in the training, we
record the loss value on the validation set every 20 epochs. After the training is done, we
roll back to the model that has the minimal recorded loss value on the validation set. Please
note that the roll-back strategy is conducted on the validation set, and we don’t use any
information of the testing set.
A.2.2 Parameters for D3I Experiments
We use tensorflow 1.9.0 to implement D3I methods. The D3I models are trained using
Adam gradient descent algorithm. The learning rate in the the Adam gradient descent
algorithm is initialized as 1e-3. The learning rate is decreased with a rate of 0.8 every 80
epochs of optimization. The parameter ε in Adam, which is used to prevent any division
by zero, is set to 1e-4. The learning rate is the same for both of the datasets.
On the FEARS dataset, in the TPTN setting, the best performing (in terms of F1) D3Imax
with TG has the following parameters: the dimension for single drug embeddings (k) is 128;
the number of fully-connected layers before the aggregator (ne) is 1; the number of fully-
connected layers after the aggregator (np) is 3. In the TPRN setting, the best performing
(in terms of F1) D3Imax with TG has the following parameters: the dimension for single
drug embeddings (k) is 128; the number of fully-connected layers before the aggregator
(ne) is 1; the number of fully-connected layers after the aggregator (np) is 0. We set the
batch size as 100 when training on all the drug combinations, and 50 when training on only
the order-2 drug combinations. We set the number of the epochs as 600 in both TPTN and
TPRN settings.
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On the BMC dataset, the best performing (in terms of F1) D3Imax with OSE has the
following parameters: the dimension for single drug embeddings (k) is 128; the number of
fully-connected layers before the aggregator (ne) is 1; the number of fully-connected layers
after the aggregator (np) is 1. The batch size on BMC is 200, and the number of learning
epochs is 400.
A.3 Additional Experimental Results
A.3.1 Comparison over Drug Features
Table A.1 presents the best performance in terms of F1 for each drug feature in FEARS
dataset in the TPRN setting. Performance in other metrics corresponding to the best F1
is also presented. For high-cardinality drug combinations as in FEARS in TPRN, the best
performing drug features are TG for D3Imax and D3Imean, and TI for D3IAtt. The reason
why TG has good performance might be that as more drugs are involved in a combination,
it is likely that the interactions among their targets and secondary targets could induce the
drug-drug interactions. Table A.2 presents the comparison over different drug features in
D3I methods on the FEARS dataset in the TPTN setting. The best performing drug features
in TPTN on FEARS is still TG. Table A.3 presents the best performance in terms of F1 for
each drug feature in BMC dataset. The results in Table A.3 show that the off-side effect
profiles OSE as drug features enable the best performance for all the three methods in terms
of F1. The drug indication profiles TI as drug features also show promising results for D3I
methods. This may be maybe because for drug pairs (all drug combines in BMC dataset
are drug pairs), side effect profiles and drug indication profiles are the most direct sources
of information that is related to pairwise drug-drug interactions.
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Table A.1.
Comparison of Drug Features on FEARS Dataset (TPRN)
method feature acc pre rec F1 AUC
D3Imax
TG 0.762 0.813 0.680 0.740 0.845
SE 0.738 0.744 0.728 0.735 0.820
TI 0.755 0.807 0.672 0.732 0.848
FP 0.699 0.693 0.718 0.704 0.767
D3Imean
TG 0.706 0.708 0.702 0.704 0.767
SE 0.679 0.656 0.760 0.703 0.756
TI 0.690 0.704 0.657 0.679 0.762
FP 0.668 0.705 0.588 0.638 0.742
D3IAtt
TI 0.703 0.750 0.609 0.672 0.760
SE 0.668 0.675 0.647 0.661 0.737
FP 0.649 0.649 0.660 0.653 0.703
TG 0.659 0.673 0.623 0.646 0.734
Column “feature” corresponds to the drug features. Columns “acc”, “pre”, “rec”,
“F1” and “AUC” correspond to accuracy, precision, recall, F1 and AUC. The best
results presented for each feature are selected based on F1. The best F1 and the
other performance evaluation over each feature are bold. The best F1 over all
the features is underlined.
A.3.2 Comparison over Model Architectures
Table A.4 and A.5 present the best performance of the three methods from different
model architectures on FEARS in the TPTN and TPRN settings, respectively. The perfor-
mance is presented in terms of F1.
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Table A.2.
Comparison of Drug Features on FEARS Dataset (TPTN)
method feature acc pre rec F1 AUC
D3Imax
TG 0.823 0.862 0.773 0.815 0.892
FP 0.817 0.838 0.786 0.811 0.882
SE 0.807 0.793 0.752 0.771 0.881
TI 0.807 0.820 0.721 0.767 0.877
D3Imean
TG 0.761 0.768 0.750 0.759 0.833
FP 0.773 0.790 0.744 0.766 0.842
SE 0.726 0.684 0.684 0.683 0.806
TI 0.724 0.733 0.588 0.652 0.786
D3IAtt
TG 0.758 0.768 0.744 0.756 0.834
FP 0.753 0.756 0.749 0.752 0.828
SE 0.742 0.728 0.644 0.683 0.805
TI 0.752 0.763 0.636 0.693 0.816
Column “feature” corresponds to the drug features. Columns “acc”, “pre”, “rec”,
“F1” and “AUC” correspond to accuracy, precision, recall, F1 and AUC. The best
results presented for each feature are selected based on F1. The best F1 and the
other performance evaluation over each feature are bold. The best F1 over all the
features is underlined.
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Table A.3.
Comparison of Drug Features on BMC Dataset (TPRN)
method feature acc pre rec F1 AUC
D3Imax
OSE 0.693 0.663 0.788 0.720 0.744
TI 0.672 0.643 0.777 0.703 0.717
FP 0.668 0.645 0.750 0.693 0.713
TG 0.643 0.621 0.739 0.674 0.684
PW 0.633 0.613 0.731 0.666 0.676
EM 0.616 0.621 0.601 0.611 0.650
TP 0.592 0.608 0.524 0.562 0.620
D3Imean
OSE 0.687 0.669 0.742 0.703 0.743
TI 0.681 0.659 0.752 0.702 0.734
FP 0.670 0.657 0.714 0.684 0.721
TG 0.654 0.643 0.698 0.669 0.707
PW 0.650 0.637 0.704 0.667 0.702
EM 0.624 0.633 0.590 0.610 0.666
TP 0.605 0.624 0.531 0.573 0.637
D3IAtt
OSE 0.670 0.635 0.803 0.709 0.710
TI 0.670 0.640 0.779 0.702 0.707
FP 0.661 0.626 0.801 0.703 0.696
TG 0.659 0.639 0.735 0.683 0.698
PW 0.638 0.611 0.761 0.678 0.681
EM 0.631 0.634 0.623 0.629 0.669
TP 0.603 0.622 0.530 0.573 0.635
Column “feature” corresponds to the drug features. Columns “acc”, “pre”, “rec”,
“F1” and “AUC” correspond to accuracy, precision, recall, F1 and AUC. The best
F1 and the other performance evaluation over each feature are bold. The best F1
over all the features is underlined.
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Table A.4.
F1 Comparison over Model Architectures (FEARS, TG, TPTN)
method #layers
embedding dimensiosn
32 64 128 256 512
D3Imax
0 0.809 0.808 0.812 0.812 0.812
1 0.809 0.811 0.814 0.809 0.808
3 0.811 0.809 0.815 0.813 0.808
5 0.806 0.810 0.814 0.809 0.805
D3Imean
0 0.721 0.723 0.722 0.722 0.724
1 0.724 0.726 0.725 0.723 0.727
3 0.735 0.732 0.731 0.741 0.751
5 0.735 0.759 0.749 0.729 0.735
D3IAtt
16 0.750 0.753 0.754 0.753 0.750
32 0.750 0.752 0.751 0.756 0.751
64 0.750 0.752 0.754 0.755 0.750
128 0.751 0.753 0.751 0.753 0.753
Column “#layers” corresponds to the number of fully-connected layers after
the aggregator. Columns under “embedding dimension” correspond to the
different numbers of embedding dimensions. The values in this Table are
F1 values under the corresponding model architectures using TG as drug
features.
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Table A.5.
F1 Comparison over Model Architectures (FEARS, TG, TPRN)
method #layers
embedding dimensiosn
32 64 128 256 512
D3Imax
0 0.730 0.734 0.740 0.738 0.740
1 0.731 0.732 0.718 0.727 0.718
3 0.707 0.710 0.695 0.683 0.688
5 0.702 0.698 0.667 0.696 0.651
D3Imean
0 0.610 0.606 0.611 0.615 0.614
1 0.673 0.673 0.680 0.683 0.683
3 0.688 0.683 0.691 0.690 0.699
5 0.699 0.704 0.692 0.687 0.691
D3IAtt
16 0.639 0.633 0.642 0.646 0.643
32 0.621 0.635 0.636 0.646 0.642
64 0.627 0.636 0.627 0.636 0.632
128 0.627 0.632 0.629 0.641 0.632
Column “#layers” corresponds to the number of fully-connected layers after
the aggregator. Columns under “embedding dimension” correspond to the
different numbers of embedding dimensions. The values in this Table are
F1 values under the corresponding model architectures using TG as drug
features.
